Ayvakit (avapritinib) Price is India

• Medicine Name- Ayvakit 
• API- Avapritinib
• Strength- it is available as Tablets: 25 mg, 50 mg, 100 mg, 200 mg and 300 mg.
• Manufactured by- Blueprint Medicines Corporation

Medicinal Uses:

Gastrointestinal Stromal Tumor (GIST):

• AYVAKIT is indicated for the treatment of adults with unresectable or metastatic GIST.
• Specifically recommended for GIST cases harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including the challenging PDGFRA D842V mutations.

Advanced Systemic Mastocytosis (AdvSM):

• AYVAKIT is approved for the treatment of adult patients diagnosed with AdvSM.
• AdvSM includes various conditions such as aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SMAHN), and mast cell leukemia (MCL).
• Limitations of Use for AdvSM: AYVAKIT is not recommended for patients with AdvSM having platelet counts less than 50 X 10^9 /L.

Indolent Systemic Mastocytosis (ISM):

• AYVAKIT is indicated for the treatment of adult patients diagnosed with Indolent Systemic Mastocytosis (ISM).
• Limitations of Use for ISM: AYVAKIT is not recommended for the treatment of patients with ISM having platelet counts less than 50 X 10^9 /L.

Note: Careful consideration of platelet counts is emphasized as a limitation of use for both AdvSM and ISM, ensuring the suitability of AYVAKIT in patients with platelet counts equal to or greater than 50 X 10^9 /L.

Recommended Dosage

Gastrointestinal Stromal Tumor (GIST):

• Patients should be selected for AYVAKIT treatment based on the presence of a PDGFRA exon 18 mutation.
• The recommended dosage for GIST is 300 mg orally once daily.

Advanced Systemic Mastocytosis (AdvSM):

• The recommended dosage for AdvSM is 200 mg orally once daily.
• Indolent Systemic Mastocytosis (ISM):

• The recommended dosage for ISM is 25 mg orally once daily.

Patients with Severe Hepatic Impairment (Child-Pugh Class C):

In cases of severe hepatic impairment (Child-Pugh Class C), the dose of AYVAKIT should be reduced. Specific guidance on dose reduction in this population should be determined based on clinical assessment and medical supervision.

Important Administration Instructions:

• AYVAKIT should be taken orally, with or without food.
• The medication should be swallowed whole with a glass of water.
• Patients should be educated on the importance of adhering to the prescribed dosage and administration schedule.

Note: Dosage adjustments and administration guidance for specific patient populations, such as those with severe hepatic impairment, should be made under the supervision of a healthcare professional, taking into account the patient's individual clinical condition and response to treatment. Regular monitoring may be necessary in such cases.

Warning and Precautions:

Intracranial Hemorrhage: Serious intracranial hemorrhage may occur; fatal events in less than 1% of patients. Monitor closely for risk factors: history of vascular aneurysm, prior intracranial hemorrhage, anticoagulant use, or thrombocytopenia. Symptoms: headache, nausea, vomiting, vision changes, altered mental status. Seek immediate medical attention.

Cognitive Effects: Cognitive adverse reactions in 33% of patients; manage with dose adjustments. Severity-dependent actions: continue at the same dose, resume at the same or reduced dose upon improvement, or permanently discontinue.

Platelet Counts and Thrombocytopenia: In AdvSM, platelet count monitoring essential. Perform every 2 weeks for the first 8 weeks, then adjust frequency based on platelet values.

Cognitive Effects in Specific Conditions: AYVAKIT patients may experience a wide range of cognitive adverse effects. Depending on the severity, patients with GIST, AdvSM, or ISM should continue taking AYVAKIT at the same dose, stop for a while and return at the same or lower dose when they feel better, or stop taking it permanently.

Photosensitivity: Photosensitivity reactions in 2.5% of patients. Advise limiting direct ultraviolet exposure during AYVAKIT treatment and for one week after discontinuation.

Embryo-Fetal Toxicity: AYVAKIT can cause fetal harm based on animal studies. Advise pregnant women of potential risk; use effective contraception during treatment and for 6 weeks after the final dose.

Documentation & Availability in India:

If you are considering the import of Ayvakit (avapritinib) to India, please be aware that Ayvakit can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Ayvakit (avapritinib) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Ayvakit (avapritinib) in India: 

Ayvakit (avapritinib) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Ayvakit (avapritinib) can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Ayvakit (avapritinib)

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Ayvakit (avapritinib) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What is AYVAKIT, and what is it used for?

AYVAKIT is a kinase inhibitor used for treating unresectable or metastatic Gastrointestinal Stromal Tumor (GIST) with specific mutations, as well as Advanced Systemic Mastocytosis (AdvSM) and Indolent Systemic Mastocytosis (ISM).

How is AYVAKIT dosed for different conditions?

The dosage varies depending on the condition: 300 mg orally once daily for GIST, 200 mg for AdvSM, and 25 mg for ISM. In severe hepatic impairment, the AYVAKIT dose should be reduced.

What are the common side effects of AYVAKIT?

Common side effects include edema, nausea, fatigue, cognitive impairment, vomiting, and diarrhea, among others.

Are there any contraindications to using AYVAKIT?

No, there are no contraindications listed for AYVAKIT.

What precautions should be taken while using AYVAKIT?

Precautions include discontinuing AYVAKIT for intracranial hemorrhage, managing cognitive effects, advising about photosensitivity, and using effective contraception due to potential embryo-fetal toxicity.

Buy Voquezna Triple Pak online in india

• Voquezna Triple Pak  (vonoprazan tablets; amoxicillin capsules; clarithromycin tablets)
• Medicine Name- vonoprazan, amoxicillin, clarithromycin 
• API- Vamorolone
• Manufactured by-  Phathom Pharmaceuticals, Inc.

Strength- 14 daily administration packs in a carton for morning and evening use, each containing one of the three medication products: Vonoprazan 20 mg tablets, Clarithromycin 500 mg tablets, and Amoxicillin 500 mg capsules

Medicinal Uses:

This co-packaged marvel is designed for the effective treatment of Helicobacter pylori (H. pylori) infection in adults.  Vonoprazan, a potent potassium-competitive acid blocker (PCAB), ensures relief from acid-related issues, promoting digestive comfort. Amoxicillin, a trusted penicillin-class antibacterial, steps in to combat bacterial intruders, bolstering your body's defense. Meanwhile, Clarithromycin, a robust macrolide antimicrobial, adds its strength to the mix, ensuring a comprehensive assault on the infection. Voquezna Triple Pak is your ally in the battle against H. pylori, offering a convenient and effective medicinal solution.

The suggested dosage is 20 mg of vonoprazan, 1,000 mg of amoxicillin, and 500 mg of clarithromycin, given twice a day, with or without meals, in the morning and evening (12 hours apart), for a total of 14 days.

Warning and Precautions:

Hypersensitivity Reactions: In rare cases, severe and potentially fatal reactions like anaphylaxis have been reported. If such reactions occur, discontinue Voquezna Triple Pak immediately and seek urgent medical attention.

Severe Cutaneous Adverse Reactions (SCAR): Cease medication at the first signs of SCAR or other hypersensitivity symptoms. Further evaluation may be necessary.

Clostridioides difficile-associated diarrhea (CDAD): Monitor for diarrhea during Voquezna Triple Pak treatment and consult healthcare providers if persistent.

Specific to Clarithromycin Component:

QT Prolongation: Avoid use in patients with known QT prolongation, ventricular arrhythmia, hypokalemia/hypomagnesemia, significant bradycardia, or those taking specific antiarrhythmics.

Hepatotoxicity: Discontinue if signs of hepatitis manifest.

Serious Adverse Reactions: Use caution with concomitant drugs due to potential interactions, especially with clarithromycin.

Embryo-Fetal Toxicity: Not recommended for pregnant women unless no alternative therapy is suitable.

Myasthenia Gravis: Exacerbation of myasthenia gravis has been reported; monitor patients accordingly.

These precautions aim to ensure patient safety and well-being during the course of Voquezna Triple Pak treatment. Always consult with healthcare professionals for personalized guidance.

Documentation & Availability in India:

If you are considering the import of Voquezna to India, please be aware that Voquezna can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

• Required Documentation for Import:
• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

• The order for Voquezna  will be confirmed upon the receipt of the following documents:
• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Voquezna  in India: 

Voquezna is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Voquezna can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Voquezna

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Voquezna in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: 

Indian Pharma Network is proficient in sourcing Voquezna   from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ's

What is Voquezna Triple Pak used for?

Voquezna Triple Pak is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. It contains vonoprazan, amoxicillin, and clarithromycin to combat the bacterial infection effectively.

How should I take Voquezna Triple Pak?

The recommended dosage is vonoprazan 20 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, twice daily (morning and evening, 12 hours apart), with or without food, for 14 days. Follow your healthcare provider's instructions carefully.

What should I do if I miss a dose?

If you miss a dose, take it as soon as you remember. However, if it's close to the next scheduled dose, skip the missed one and continue with the regular dosing schedule.

Are there any potential side effects of Voquezna Triple Pak?

Like any medication, Voquezna Triple Pak may have side effects. Common ones include nausea, diarrhea, and headache. However, serious reactions can occur, so contact your healthcare provider if you experience any unusual symptoms.

Can I take other medications while on Voquezna Triple Pak?

Inform your healthcare provider about all medications, supplements, or herbal products you are taking. Some drugs may interact with Voquezna Triple Pak, potentially leading to adverse effects.

Is Voquezna Triple Pak safe during pregnancy?

The use of Voquezna Triple Pak during pregnancy is generally not recommended unless there are no alternative therapies. Pregnant individuals should consult their healthcare provider to assess potential risks and benefits.

Cibinqo (Abrocitinib) price in India

Abrocitinib

Medicine Name: Cibinqo 

API: Abrocitinib

Dosage Forms & Strengths: 50 mg, 100 mg, and 200 mg tablets

Manufactured by: ImmunoGen

Medicinal Uses

Abrocitinib is used to treat moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and above, who haven't responded well to other systemic drugs or when using those treatments isn't recommended.

Recommended Dosage:

• Starting Dose: Take 100 mg orally once daily.
• Adjustment: If the response is inadequate, the doctor may increase the dose to 200 mg daily.
• Special Situations: For moderate kidney issues or specific metabolic conditions, the dosage may be adjusted.
• Regular Check-ups: Regular check-ups and tests are needed to monitor your health during treatment.
• Precaution: Avoid using Abrocitinib with other JAK inhibitors or certain immunosuppressants.

Warnings and Precautions:

• Infections: Serious bacterial, fungal, or viral infections may occur. TB testing is required before and during treatment.
• Mortality Risk: Some patients have a higher risk of all-cause mortality, including cardiovascular complications.
• Cancer Risk: Instances of lymphomas and lung cancers have been reported.
• Heart and Blood Clot Risks: Issues like heart problems and blood clots have occurred in some cases.

Documentation & Availability in India:

If you are considering the import of Abrocitinib to India, please be aware that Abrocitinib can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

A valid prescription from a qualified medical practitioner.

Diagnostic reports of the patient.

Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Abrocitinib will be confirmed upon the receipt of the following documents:

A valid prescription from a qualified doctor.

An import permit, if applicable.

Availability of Abrocitinib in India: 

Abrocitinib is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Abrocitinib can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Abrocitinib (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Abrocitinib in India and to initiate the ordering process, please reach out to us through the following contact details:

Phone: +91-9310090915

Toll-Free Number: 1800-889-1064

Email: info@indianpharmanetwork.in

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Abrocitinib from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ’s

What is Abrocitinib used for?

Abrocitinib is used to treat moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and above when other systemic drugs haven't worked or are not recommended.

How should I take Abrocitinib?

The typical starting dose is 100 mg orally once daily. Your doctor may adjust this to 200 mg daily if the initial response is inadequate. Specific dosage adjustments might apply in certain health conditions.

What should I be cautious about while taking Abrocitinib?

It's essential to avoid using Abrocitinib with other JAK inhibitors or specific immunosuppressants. Additionally, regular health check-ups and tests are necessary during treatment.

Are there any significant risks associated with Abrocitinib?

Yes, serious infections (bacterial, fungal, or viral), increased mortality risk, potential for developing cancers like lymphomas and lung cancers, and risks related to heart problems and blood clots have been observed in some cases.

Do I need any specific tests before or during Abrocitinib treatment?

Yes, it's crucial to undergo TB testing before and during treatment due to the risk of serious infections. Regular health monitoring will also be necessary to ensure your safety during the course of treatment.

Toripalimab : Metastatic Nasopharyngeal Carcinoma

 According to a randomized trial, "Adding the investigational PD-1 immune checkpoint inhibitor toripalimab to standard frontline chemotherapy significantly helps in order to delay the disease progression in patients with the recurrent/metastatic nasopharyngeal carcinoma.

Outcomes from the phase-III JUPITER-2 trial demonstrated that the addition of toripalimab significantly improved the progression-free survival (PFS) in comparison to placebo, with a median 11.7 months in comparison to 8.0 months (HR 0.52, 95 percent CI 0.36 to 0.74, P=0.0003), reported Rui-Hua Xu, MD, PhD, of the Sun Yat-Sen University Cancer Center in Guangzhou in China. 

Speaking at a press briefing in advance of the virtual American Society of Clinical Oncology (ASCO) annual meeting, Xu said, "In an interim analysis of overall survival (OS), toripalimab plus gemcitabine/cisplatin also demonstrated benefit over placebo."

"The combination was safe, and no new safety signals were noted," he added. "The outcomes favor the use of toripalimab together with the gemcitabine-cisplatin regimen as the new standard of care for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Nasopharyngeal carcinoma (NPC), is the most common cancer originating in nasopharynx, most commonly in the postero-lateral nasopharynx or pharyngeal recess (fossa of Rosenmüller), accounting for 50% of cases. Nasopharyngeal carcinoma occurs in children and adults. This carcinoma significantly differs from other existing cancers of the head and neck in its occurrence, causes, clinical nature, and treatment. NPC is vastly more common in East Asia and Africa than elsewhere, with viral, dietary and genetic factors implicated in its causation. 

Although the current standard first-line treatment for the recurrent or metastatic nasopharyngeal carcinoma is gemcitabine-cisplatin chemotherapy, the duration of the response is typically less than 6 months.

Toripalimab, a monoclonal antibody specific for PD-1, is approved in China as a monotherapy in the 2'nd or 3'rd-line setting, where it has demonstrated durable responses in patients with recurrent/metastatic disease.

In JUPITER-2, a total of 289 patients receiving gemcitabine-cisplatin in the first-line setting were randomized 1:1 to either toripalimab or placebo. Patients were treated with chemo plus toripalimab or placebo every 3 weeks for up to 6-cycles, followed by the toripalimab or placebo every 3 weeks until disease progressed.

The 1-year progression-free survival rate was 49.4% in the toripalimab arm compared with 27.9% in the placebo arm. The overall survival rates at 2 years were noted as 77.8% with toripalimab vs 63.3% with placebo.

Regarding safety, the incidence of grade ≥3 adverse events (AEs) was identical in both the arms (89.0% for the toripalimab patients and 89.5% for the placebo group), Xu reported. 

The rate of adverse events leading to the interruption of treatment was also identical (7.5% vs 4.9%, respectively), as were fatal adverse events (2.7% vs 2.8%, respectively). Immune-related adverse events, however, were significantly higher in the toripalimab arm (39.7% vs 18.9%), as were immune-related grade ≥3 adverse events (7.5% vs 0.7%).

American Society of Clinical Oncology Chief Medical Officer and Executive Vice President Julie R. Gralow, MD, commented at the briefing that while treatment advances for the nasopharyngeal carcinoma have lagged behind those of other cancers.

Toripalimab got the breakthrough designation by the (FDA) Food and Drug Administration for the recurrent/metastatic nasopharyngeal carcinoma, fast track and orphan drug status for the certain other types of cancer.

With Food and Drug Administration approval these findings should be proved to be practice changing," Julie R. Gralow said.

Reference: https://www.onclive.com/view/frontline-toripalimab-plus-gemcitabine-cisplatin-significantly-improves-pfs-in-recurrent-or-metastatic-nasopharyngeal-carcinoma

Ponatinib for Chronic Myeloid Leukaemia

 What is Iclusig used for?

As a kinase inhibitor Iclusig is recommended for the treatment of adults patients with:

chronic phase chronic myeloid leukemia (CML) who didn't get benefit from treatment with at least 2 prior kinase inhibitor medications. 

accelerated phase or blast phase CML, or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are not able to take any other kinase inhibitor drugs. 

What are the side effects of iclusig? 

The most common side effects of Iclusig may include:

• fever
• nausea
• skin rash 
• joint pain 
• abdomen pain
• headache 
• constipation
• dry skin
• high blood pressure 
• tiredness
• bleeding
• low hemoglobin in the blood 
• liver problems
• low blood platelet counts
• inflammation of the pancreas

Report to your healthcare practitioner in case you experience any side effect that is persistent and bothers you. 

What is the recommended dosage of iclusig? 

The starting dose of Iclusig is 45 mg, which should be given orally once in a day. Reducing the iclusig dosage is considered for patients with chronic phase CML and accelerated phase CML who have achieved a major cytogenetic response. Iclusig tablets should be consumed with or without food. Tablets required to be swallowed whole.

What dosage forms and strength iclusig comes? 

This medication is available in the form of tablets as following strength:

• iclusig 15 mg tablet
• iclusig 30 mg tablet
• iclusig 45 mg tablet

Is ponatinib a chemotherapy drug?

Ponatinib mainly is a type of targeted cancer drug. It is also known by its brand name Iclusig. It blocks as well as interferes with a number of protein kinases. 

What are the drug interactions with iclusig? 

This drug may interact when it is used with other drugs. Some possible iclusig drug interactions are as follows:

Coadministration of carbamazepine, phenytoin, rifampin, and St. John’s Wort (strong CYP3A inducers) together with iclusig tablets must be avoided. 

When using iclusig together with strong CYP3A inhibitors (e.g. ritonavir, indinavir, boceprevir, conivaptan, itraconazole, clarithromycin, nelfinavir, ketoconazole, lopinavir/ritonavir, posaconazole, saquinavir, telaprevir, telithromycin, nefazodone, voriconazole), the recommended initial dose needs to be reduced. 

How much does iclusig cost? 

In India, the cost of iclusig is quite reasonable. The iclusig 45 mg price is around $17,299 for a supply of 30 tablets. Prices may vary depending on branded to non-branded (generic) drugs. 

Where can I get Iclusig at a best price? 

In order to get the best iclusig price, always go with a pharmaceutical wholesaler company that holds the WHO-GDP & ISO certification. 

How should I store Iclusig?

Iclusig tablets should be placed at room temperature between 68°F - 77°F (20°C-25°C). Keep these tablets and all medicines out of the reach of children.

Exkivityt (mobocertinib) Capsules

A kinase inhibitor called EXKIVITY is prescribed for adult patients whose disease has progressed during or following platinum-based chemotherapy and who have locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as determined by an FDA-approved test.

Recommended Dosage:

160 mg taken once daily, with or without food, is the recommended dosage. 

Warnings and Precautions:

Lung and Breathing Problems:

Keep an eye on any new or worsening breathing problems while taking Exkivity. If you have signs like trouble breathing or coughing, tell your doctor right away. They might stop Exkivity if they suspect a lung problem.

Heart Health:

Your heart's health will be checked before and during Exkivity treatment. If there are concerns about how your heart is working, the dosage might change or the medication might be stopped.

Dealing with Diarrhea:

Diarrhea might happen while you're on Exkivity. It could lead to dehydration or issues with your body's balance of minerals. Your doctor might suggest medicine for diarrhea and ask you to drink more fluids. They could adjust the Exkivity dose if it becomes severe.

Pregnancy Precautions:

If you can get pregnant, be aware that Exkivity might harm an unborn baby. It's important to use effective non-hormonal birth control while taking Exkivity to prevent pregnancy.

Documentation & Availability in India:

If you are considering the import of Exkivity (Mobecertinib succinate)  to India, please be aware that Exkivity can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order for Exkivity will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Exkivity in India: 

Exkivity (Mobecertinib succinate)  is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Exkivity can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Exkivity (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Exkivity in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcingExkivity (Mobecertinib succinate)  from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

FAQ’s

What is Exkivity (Mobocertinib succinate)?

Exkivity, also known as Mobocertinib succinate, is an oral medication used for the treatment of non-small cell lung cancer (NSCLC). Specifically, it targets tumors with certain mutations in the epidermal growth factor receptor (EGFR) gene, such as exon 20 insertion mutations, which are typically resistant to other EGFR inhibitors.

How does Exkivity work?

Exkivity is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of mutated EGFR proteins in cancer cells. EGFR mutations, especially exon 20 insertions, can drive the growth of cancer cells. Exkivity inhibits the abnormal signaling caused by these mutations, thereby slowing down or halting the growth of cancer cells.

What are the common side effects of Exkivity?

Common side effects of Exkivity may include diarrhea, rash, nausea, vomiting, fatigue, decreased appetite, mouth sores, and abdominal pain. Additionally, Exkivity can cause more serious side effects such as interstitial lung disease/pneumonitis, liver problems, and heart problems.

How is Exkivity taken?

Exkivity is taken orally in the form of tablets. The typical recommended dosage is usually once daily with or without food. Dosage and administration may vary based on individual patient factors and should be taken as directed by a healthcare professional.

Who is a candidate for Exkivity treatment?

Exkivity is approved for adult patients with NSCLC that have specific EGFR mutations, particularly exon 20 insertion mutations, and have progressed after previous treatment or are unable to tolerate other EGFR inhibitors. Patients should undergo genetic testing to confirm the presence of these mutations before starting treatment with Exkivity.

Adbry Price in India

Medicinal Uses

Tralokinumab-ldrm injection is an interleukin-13 antagonist indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients. This is for individuals whose condition remains inadequately controlled with topical prescription therapies or when these therapies are not advisable. Tralokinumab-ldrm can be used in combination with or without topical corticosteroids.

Recommended Dosage:

Before starting Tralokinumab-ldrm treatment, ensure all age-appropriate vaccinations as recommended by current immunization guidelines are completed. The recommended dosage includes an initial dose of 600 mg (four injections of 150 mg each), followed by 300 mg (two 150 mg injections) administered every other week. For patients below 100 kg achieving clear or almost clear skin after 16 weeks, a dosage of 300 mg every 4 weeks may be considered. Tralokinumab-ldrm is administered through subcutaneous injection.

Warnings and Precautions:

Hypersensitivity: Anaphylaxis and angioedema have been reported after Tralokinumab-ldrm administration. Discontinue Tralokinumab-ldrm in case of hypersensitivity reactions.

Conjunctivitis and Keratitis: Patients should promptly report any new or worsening eye symptoms to their healthcare provider.

Parasitic (Helminth) Infections: Address pre-existing helminth infections before starting Tralokinumab-ldrm. If infections occur during treatment and don't respond to anti-helminth treatment, discontinue Tralokinumab-ldrm until the infection resolves.

Risk of Infection with Live Vaccines: Avoid the use of live vaccines while on Tralokinumab-ldrm treatment.

Documentation & Availability in India:

If you are considering the import of Tralokinumab to India, please be aware that Tralokinumab-ldrm can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
• Diagnostic reports of the patient.
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

• The order for Elahere will be confirmed upon the receipt of the following documents:
• A valid prescription from a qualified doctor.
• An import permit, if applicable.

Availability of Tralokinumab-ldrm in India: 

Tralokinumab is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Tralokinumab-ldrm can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Tralokinumab-ldrm (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Tralokinumab-ldrm in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Sourcing & Delivery: Indian Pharma Network is proficient in sourcing Tralokinumab-ldrm from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient's address, exclusively from New Delhi, India.

What is Tralokinumab-ldrm used for?

Tralokinumab-ldrm is an interleukin-13 antagonist prescribed for the treatment of moderate-to-severe atopic dermatitis in adults. It's specifically for patients whose condition isn't adequately controlled with topical prescription therapies or when using those therapies isn't advisable.

How is Tralokinumab-ldrm administered?

Tralokinumab-ldrm is administered through subcutaneous injection. The typical dosage includes an initial dose of 600 mg (four injections of 150 mg each), followed by a maintenance dose of 300 mg (two 150 mg injections) every other week. Some patients achieving clearer skin after 16 weeks might have their dosage adjusted to 300 mg every 4 weeks.

Can Tralokinumab-ldrm be used in combination with other medications?

Tralokinumab-ldrm can be used with or without topical corticosteroids. However, it is not recommended to be used in combination with other JAK inhibitors or certain immunosuppressants.

Are there any conditions where Tralokinumab-ldrm should not be used?

Tralokinumab-ldrm should not be used in individuals with a known hypersensitivity to tralokinumab-ldrm or any components present in the medication.

What precautions should be taken while using Tralokinumab-ldrm?

Some precautions include careful monitoring for hypersensitivity reactions, prompt reporting of new or worsening eye symptoms, treating pre-existing helminth infections before starting Tralokinumab-ldrm, avoiding live vaccines during treatment, and regular check-ups and tests to monitor health during treatment.